A Novel Diagnostic Marker in Pulmonary Thromboembolism? Platelet-Derived Growth Factor –β

Abstract

Objective: Pulmonary thromboembolism (PTE) is a condition characterized by severe cardiopulmonary injury. There is a need for a cheap and reliable biochemical marker, which is also easily and rapidly accessible, with high specificity and sensitivity in the diagnosis of PTE. The PDGF ligand receptor system plays a role in the development of pulmonary hypertension and contributes to thickening of the vascular wall and increasing the wall tension. In the present study, we aimed to investigate whether plasma PDGF-B levels increase in patients with PTE and the diagnostic value of PDGF-B in PTE along with its relationship with mortality. Methods: This prospective clinical study was conducted in the emergency department of a tertiary university hospital between March 1st, 2020 and March 1st, 2021. A total of 44 patients diagnosed as having PTE in the emergency department (patient group) and 34 healthy volunteers without any chronic disease (control group) were included in our study. Results: The PDGF-β levels of the patients diagnosed as having PTE in the ED were found to be significantly higher than those of patients in the control group (Z=-2.015, p=0.044). There was no significant linear relationship between PDGF-β levels and age, gender, presence of chronic disease, systolic and diastolic blood pressure as well as peak heart rate, respiratory rate, and axillary body temperature values at the time of admission to the emergency department, Geneva, Wells and PESI scores. In our study, no significant linear relationship was found between PDGF-β and D-Dimer levels in patients with PTE and mortality. Conclusion: The results obtained from this study, which investigated whether PDGF-B was a new prognostic biomarker for PTE, suggest that plasma PDGF-B levels are significantly higher in PTE cases and can aid in the diagnosis of PTE. However, PDGF-B cannot be used as a marker to predict prognosis

Keywords

• Biomarker
• mortality
• PDGF-B
• pulmonary thromboembolism
• Biomarker, mortality, PDGF-B, pulmonary thromboembolism

A Novel Diagnostic Marker in Pulmonary Thromboembolism? Platelet-Derived Growth Factor –β

Abstract

Objective: Pulmonary thromboembolism (PTE) is a condition characterized by severe cardiopulmonary injury. There is a need for a cheap and reliable biochemical marker, which is also easily and rapidly accessible, with high specificity and sensitivity in the diagnosis of PTE. The PDGF ligand receptor system plays a role in the development of pulmonary hypertension and contributes to thickening of the vascular wall and increasing the wall tension. In the present study, we aimed to investigate whether plasma PDGF-B levels increase in patients with PTE and the diagnostic value of PDGF-B in PTE along with its relationship with mortality. Methods: This prospective clinical study was conducted in the emergency department of a tertiary university hospital between March 1st, 2020 and March 1st, 2021. A total of 44 patients diagnosed as having PTE in the emergency department (patient group) and 34 healthy volunteers without any chronic disease (control group) were included in our study. Results: The PDGF-β levels of the patients diagnosed as having PTE in the ED were found to be significantly higher than those of patients in the control group (Z=-2.015, p=0.044). There was no significant linear relationship between PDGF-β levels and age, gender, presence of chronic disease, systolic and diastolic blood pressure as well as peak heart rate, respiratory rate, and axillary body temperature values at the time of admission to the emergency department, Geneva, Wells and PESI scores. In our study, no significant linear relationship was found between PDGF-β and D-Dimer levels in patients with PTE and mortality. Conclusion: The results obtained from this study, which investigated whether PDGF-B was a new prognostic biomarker for PTE, suggest that plasma PDGF-B levels are significantly higher in PTE cases and can aid in the diagnosis of PTE. However, PDGF-B cannot be used as a marker to predict prognosis.

Keywords

• Biomarker
• mortality
• PDGF-B
• pulmonary thromboembolism
• Biomarker, mortality, PDGF-B, pulmonary thromboembolism

References

1. 1.Bruzelius M, Iglesias MJ, Hong MG, et al. PDGFB, anew candidate plasma biomarker for venousthromboembolism: Results from the VEREMAaffinity proteomics study. Blood. 2016; 128: e59-66.
2. 2.Alhabibi AM, Eldewi DM, Wahab MAA, et al.Platelet-derived growth factor-beta as a new markerof deep venous thrombosis. J Res Med Sci. 2019; 24:48.
3. 3.Spronk HM, Cannegieter S, Morange P, et al.Theme 2: epidemiology, biomarkers, and imaging ofvenous thromboembolism (and postthromboticsyndrome). Thromb Res. 2015; 136 (Suppl 1): 8-12.
4. 4.Yurdakul S, Aytekin S. Diagnostic algorithms inpulmonary hypertension. Anadolu Kardiyol Derg.2010; 10 (Suppl 1): 14-26.